Open Nav

Please submit your session questions in advance at


  • William Rust, SERAXIS INC.

Seraxis, Inc. is a private biotech company with a mission of bringing cell replacement therapies to patients in need. With several products in development, its lead product, SR-01, is a novel combination product for type 1 diabetes with an IND application anticipated for 2020. SR-01 comprises of lab-grown human pancreatic islets encased within a novel bi-layered encapsulation device that protects the cells from cytotoxic alloimmune response. The Seraxis researchers are able to create functionally mature human insulin-secreting islets at a level and purity never before reported through a combination of a proprietary iPS cell line and a novel cell differentiation protocol. The retrievable encapsulation device employs biocompatible components and enables the cells to have close association to the host vasculature to physiologically regulate blood glucose. These proprietary technologies have been developed using GMP-processes and are characterized for clinical use.

  • Date:Monday, February 11
  • Time:10:45 AM - 11:00 AM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance:

    Click here.

  • Company Presentation - Presentation Type:Privately Funded Company
  • Submission ID:22908
  • Goal for Presentation:Describe a novel promising combination regenerative therapy for treating insulin-dependent diabetes
  • Company
  • Company HQ City:Germantown
  • Company HQ State:Maryland
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:10,000,000
  • Year Founded:2013
  • Main Therapeutic Focus:Metabolic Diseases
  • Lead Product in Development:SR-01 Cell Replacement Therapy for Insulin-Dependent Diabetes
  • Development Phase of Primary Product:Pre-Clinical
  • Additional Information/Comments:Seraxis has been successful at delivering results for its shareholders in a very efficient manner, making the company an attractive investment opportunity. In addition to a management team with strong pharmaceutical background, Seraxis benefits from the guidance of world-class scientific advisors, and an experienced Board of Directors. To complete the remaining IND-enabling studies, discussed at a recent FDA pre-IND meeting, and launch its first-in-human trial at a major transplant center, Seraxis is opening a new round of financing.
William Rust